Continuous subcutaneous insulin infusion vs. multiple daily injections

Background Intensive insulin therapy should be proposed for most type 1 diabetic patients. It can be achieved by a continuous subcutaneous insulin infusion (CSII) or by multiple daily injections (MDI). Debate remains regarding the optimal delivery of such therapy. Aim To compare the efficacy of glyc...

Full description

Saved in:
Bibliographic Details
Published in:Central European journal of medicine 2011-10, Vol.6 (5), p.575-581
Main Authors: Radenkovic, Sasa P, Pesic, Milica M, Velojic Golubovic, Milena D, Dimic, Dragan N, Radojkovic, Danijela B, Iric, Vojislav M, Kocic, Radivoj D
Format: Article
Language:English
Subjects:
Biomedicine
Blood glucose control
Continuous subcutaneous insulin infusion (CSII)
Hypoglycemia
Insulin analogues
Intensive insulin therapy (IIT)
Internal Medicine
Maternal and Child Health
Medicine
Medicine & Public Health
Multiple daily injections (MDI)
Reproductive Medicine
Research Article
Surgery
Type 1 diabetes mellitus
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Intensive insulin therapy should be proposed for most type 1 diabetic patients. It can be achieved by a continuous subcutaneous insulin infusion (CSII) or by multiple daily injections (MDI). Debate remains regarding the optimal delivery of such therapy. Aim To compare the efficacy of glycemic control, hypoglycemia frequency, dose of insulin and weight in the type 1 diabetic patients, after switching from MDI to CSII. Methods In this retrospective study we analyzed HbA1c, profiles of blood glucose, weight, dose of insulin and hypoglycemia, 6 months before and 6 months after the initiation of CSII, in 18 patients with type 1 diabetes mellitus. Results Blood glucose control is considerably improved during CSII, as measured by HbA1c and mean blood glucose concentrations. Fasting blood glucose, postprandial glucose and also of glycemic variability were significantly lower. The total insulin doses during the CSII period were significantly lower. There was a small non significant increase in weight during CSII. There was a significant decrease in a number of mild hypoglycemic events, a small non significant decrease of asymptomatic hypoglycemia and a small non significant increase of nocturnal hypoglycemia. Conclusions CSII provides significant improvement of blood glucose control with lower risk for hypoglycemia.
ISSN:1895-1058
2391-5463
1644-3640
2391-5463
DOI:10.2478/s11536-011-0064-7